Legend Biotech Reports Preliminary Q2 CARVYKTI Sales of ~$657M, Up 62% YoY
LEGN sits 57% above its 52-week low of $16.24.
Summary
Legend Biotech announced preliminary Q2 2026 CARVYKTI net trade sales of approximately $657 million, reflecting continued strong growth for its flagship CAR-T therapy.
Key Events · Earnings and Guidance · LEGN
-
Preliminary Q2 CARVYKTI Sales
CARVYKTI generated approximately $657 million in net trade sales during Q2 2026, based on unaudited data from partner Janssen.
-
Strong Year-Over-Year Growth
The $657 million figure represents roughly 62% growth compared to Q2 2025, continuing the momentum from Q1 2026's 62% increase.
-
Commercial Execution
The sales performance underscores successful manufacturing scale-up and expanding market adoption, supporting Legend Biotech's revenue trajectory.
-
Unaudited Preliminary Data
The sales figure is preliminary and subject to finalization in Legend Biotech's Q2 2026 financial statements; actual revenue recognition may differ.
Analysis · LEGN · Life Sciences
CARVYKTI continues its rapid commercial ramp, generating approximately $657 million in preliminary net trade sales for Q2 2026. That marks roughly 62% growth over the prior-year quarter and extends the strong trajectory seen in Q1. The unaudited figure, provided by partner Janssen, signals robust demand and successful manufacturing scale-up. Against a backdrop of recent positive clinical data for pipeline assets, this commercial execution reinforces Legend Biotech's position as a leader in cell therapy.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LEGN was trading at $25.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.8B. The 52-week trading range was $16.24 to $45.30. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.